Table 2.
Transplant Characteristics
| Characteristics | Transplantation |
|---|---|
| Total, n | 20 |
| Age at transplantation (years): median (range) | 32 (16–53) |
| Sex: M/F, n (%) | 11/9 |
| ELN risk at first diagnosis, n (%) | |
| High risk | 7 (35.0) |
| Standard or intermediate risk | 13 (65.0) |
| Disease stage in transplant, n (%) | |
| CR1 | 15 (75.0) |
| ≥CR2 | 3 (15.0) |
| No remission after relapse | 2 (10.0) |
| Graft sources, n (%) | |
| Cord blood | 15 (75.0) |
| PBSC from matched sibling donor | 4 (20.0) |
| Autologous PBSC | 1 (5.0) |
| Myeloablative conditioning regimen, n (%) | |
| BUCY2-based conditioning | 12 (60.0) |
| TBICY-based conditioning | 8 (40.0) |
| GVHD Prophylaxis, n (%) | |
| CSA + MMF | 17 (85.0) |
| CSA + MMF+ MTX | 2 (10.0) |
| Total nucleated-cell dose, median (range) (×107/kg) | |
| Cord blood | 2.9 (2.1–3.7) |
| PBSC from matched sibling donor | 68.2 (45.6–93.1) |
| Total CD34+ cell dose, median (range) (×105/kg) | |
| Cord blood | 2.2 (0.83–4.6) |
| PBSC from matched sibling donor | 52.8 (22.6–88.5) |
| Neutrophil engraftment(days), median (range) | |
| Cord blood | 19.7 (16–25) |
| PBSC from matched sibling donor | 11.8 (11–14) |
| Platelet engraftment(days), median (range) | |
| Cord blood | 40.7 (19–65) |
| PBSC from matched sibling donor | 13.3 (12–15) |
| Grade Ⅱ-Ⅳacute GVHD, n | |
| Cord blood | 2 |
| PBSC from matched sibling donor | 0 |
| Chronic GVHD, n | |
| Cord blood | 3 |
| PBSC from matched sibling donor | 1 |
| Follow-up among survivors, (months), median (range) | 38.7 (15–70) |
Abbreviations: CR, complete remission; PBSC, peripheral blood stem cell; BUCY, busulfan and cyclophosphamide; TBICY, total body irradiation and cyclophosphamide GVHD, graft-versus-host disease CSA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate.